Scinai Biopharma Services Taps Industry Veteran to Lead Yavne CDMO Facility
Event summary
- Eilon Elmalem appointed Site Head of Scinai Biopharma Services' Yavne CDMO facility, effective June 14, 2026.
- Elmalem brings 20+ years of experience in engineering and operations from roles at Merck and Sigma-Aldrich Millipore.
- Transition process began May 10, 2026, with current site head Dr. Sylvia Kachalsky overseeing handover before retirement.
- Scinai acquired the Yavne facility from Recipharm, with Elmalem tasked with expanding operational capabilities.
The big picture
Scinai's appointment of Eilon Elmalem as Site Head of its Yavne CDMO facility underscores its strategic focus on operational excellence and expansion within the contract manufacturing sector. The move comes as the company integrates the recently acquired Yavne facility from Recipharm, highlighting the importance of leadership with deep industry experience in managing complex organizational transformations and GMP manufacturing facilities. This shift aligns with broader industry trends toward consolidation and operational efficiency in biopharmaceutical manufacturing.
What we're watching
- Operational Integration
- How smoothly the transition of leadership and integration of the Yavne facility will proceed under Elmalem's direction.
- Growth Strategy
- Whether Scinai can leverage Elmalem's experience to accelerate the expansion of its CDMO platform.
- Commercial Collaboration
- The pace at which Scinai can solidify and expand its commercial collaboration framework with Recipharm.
Related topics